August 2012
-
According to a LinkedIn post by generic device maker Merxin, the FDA has indicated that Merxin’s MRX004 soft mist inhaler is suitable for an ANDA submission for a generic version of Boehringer Ingelheim’s Spiriva Respimat… Read more . . .
-
Philip Morris International (PMI) has acquired inhaled drug developer OtiTopic, as “part of PMI’s strategic plan to leverage its expertise, scientific know-how, and capabilities in inhalation to grow a pipeline of inhaled therapeutics and respiratory… Read more . . .
-
Ji Xing Pharmaceuticals has acquired Chinese development and commercialization rights to Oyster Point Pharma’s OC-01 varenicline nasal spray and OC-02 simpinicline nasal spray for the treatment of dry eye disease in a deal that includes… Read more . . .
-
According to ReCode Therapeutics, studies of its nebulized lipid nanoparticle DNAI1 mRNA therapy for the treatment of primary ciliary dyskinesia in non-human primates demonstrated that a single dose of the mRNA could be delivered successfully… Read more . . .
-
According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry… Read more . . .
-
Berry Global has announced that it will construct a new facility in Bangalore, India that will serve as an R&D center and will add manufacturing capacity for devices, including nasal spray pumps and inhalers, to… Read more . . .
-
MannKind and NRx Pharmaceuticals will work together on a possible inhaled dry powder aviptadil based on MannKind’s Technosphere particle technology, the companies have announced. MannKind said that it would conduct the feasibility study at its… Read more . . .
-
According to Relief Therapeutics, the FDA has granted orphan drug designation for RLF-100 inhaled aviptadil for the treatment of sarcoidosis; RLF-100 is currently in Phase 2 development for that indication. Relief also recently acquired German… Read more . . .
-
Sanofi has agreed to pay approximately $3.2 billion for Translate Bio, which is developing inhaled mRNA therapies for cystic fibrosis, primary ciliary dyskinesia, and pulmonary arterial hypertension in addition to a number of intramuscular mRNA vaccines,… Read more . . .
-
Glenmark Pharmaceuticals has acquired the rights to manufacture and sell SaNOtize’s nitric oxide nasal spray (NONS) in India and at least a dozen other markets in Asia for the treatment of COVID-19, the companies have… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.